In order to avoid a public health crisis and keep up with increasing vision loss among the aging baby-boomer generation, correctable vision impairments must be eliminated by 2030, according to a report issued by the National Academies of Sciences, Engineering, and Medicine (NASEM).
Ben Gaddie, OD, FAAO, Optometry Times Editorial Advisory Board member, noted several specific areas that were advancing to give ODs better data and better control over patient health outcomes, including:
• Corneal mechanics
• 24-hour IOP monitoring
• New glaucoma drugs and drug delivery systems
• Advancements in OCT imaging
Clinicians can predict which patients with ocular hypertension are most likely to develop primary open-angle glaucoma (POAG) using short-wave automated perimetry, scanning laser polimetry, and confocal laser ophthalmoscopy, as well as the patient’s age, researchers said.
Clinicians will soon have another treatment option for their patients with non-severe primary open-angle glaucoma (POAG). A micro invasive glaucoma surgical (MIGS) device (CyPass Micro-Stent, Alcon) has been approved by the FDA for use in patients with mild-moderate PAOG in conjunction with cataract surgery.
Ab-interno canaloplasty (ABiC) is a minimally invasive glaucoma surgery that accesses, catheterizes, and viscodilates all sites controlling aqueous outflow. When performed alone for uncontrolled glaucoma or with cataract surgery, it can result in reduced IOP and daily medication at follow-up through 12 months.